Medicinova (MNOV) Cash & Equivalents (2010 - 2026)

Medicinova (MNOV) has reported Cash & Equivalents for 16 consecutive years, with $30.8 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents fell 23.67% year-over-year to $30.8 million; the TTM figure through Dec 2025 stood at $30.8 million (down 23.67% YoY), while the FY2025 annual figure was $30.8 million, down 23.67% from the prior year.
• Cash & Equivalents declined to $30.8 million in Q4 2025 per MNOV's latest filing, from $32.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $77.8 million in Q2 2021 and bottomed at $18.5 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $51.2 million across 5 years, with a median of $51.3 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 74.09% — and 2023, when it surged 175.59%.
• Medicinova's Cash & Equivalents stood at $71.4 million in 2021, then plunged by 74.09% to $18.5 million in 2022, then soared by 175.59% to $51.0 million in 2023, then retreated by 20.86% to $40.4 million in 2024, then decreased by 23.67% to $30.8 million in 2025.
• Business Quant data shows MNOV's Cash & Equivalents at $30.8 million in Q4 2025, $32.6 million in Q3 2025, and $34.3 million in Q2 2025.